Helicobacter pylori (H. pylori) , one of the Gram-negative spiral-shaped flagellated bacteria, colonizes the stomach of more than half of the global population. Although H. pylori has been defined as a class I carcinogen by International Agency for Research on Cancer since 1994, the pathogenesis and drug-resistance mechanism of this bacteria are still unclear. A range of virulence factors including urease, motility, adhesive ability, intracellular survival ability, biofilm formation and some toxic factors (cagA, vacA, etc) play a key role in its infection and pathogenesis. Investigations on the pathogenesis of H. pylori infection are extremely valuable for new drug development. The increasing drug-resistance of H. pylori results in the treatment failure of triple or quadruple therapy, besides, the therapeutic protocol of H. pylori-related diseases such as chronic atrophic gastritis, spasmolytic peptide-expressing metaplasia, intestinal metaplasia and even intraepithelial neoplasia are still limited. The limitations of conventional therapy divert people's attention to complementary and alternative medicine, and some traditional medicine (herbal and animal medicine in China, Japan, Brazil, and Africa, for example) have been proven to have therapeutic effects on H. pylori-induced gastric diseases. More scientific research focused on the effect and mechanism of traditional medicine is absolutely necessary and significant.
This research topic aims at elucidating the pathogenesis of Helicobacter pylori-induced diseases and providing insights into therapy, including novel therapeutic approaches and traditional medicines. Submissions on the following specific topics are welcome:
• The mechanism underlying the pathogenesis of H. pylori-induced chronic atrophic gastritis, spasmolytic peptide-expressing metaplasia, intestinal metaplasia, intraepithelial neoplasia and gastric cancer.
• Basic or clinical studies focused on traditional medicine for the treatment of H. pylori-related gastric diseases (including chemical agent-induced models similar to H. pylori infection).
• Basic or clinical studies on novel therapeutics for the treatment of H. pylori-related disease (including alternatives or adjuncts to antibiotic therapy)
• The specific survival and infection strategies of H. pylori and the mechanism of its stable colonization in the stomach
• The role of anti-acid, motile, adhesive, biofilm formation, and intracellular survival ability in the pathogenesis of H. pylori-induced diseases.
Helicobacter pylori (H. pylori) , one of the Gram-negative spiral-shaped flagellated bacteria, colonizes the stomach of more than half of the global population. Although H. pylori has been defined as a class I carcinogen by International Agency for Research on Cancer since 1994, the pathogenesis and drug-resistance mechanism of this bacteria are still unclear. A range of virulence factors including urease, motility, adhesive ability, intracellular survival ability, biofilm formation and some toxic factors (cagA, vacA, etc) play a key role in its infection and pathogenesis. Investigations on the pathogenesis of H. pylori infection are extremely valuable for new drug development. The increasing drug-resistance of H. pylori results in the treatment failure of triple or quadruple therapy, besides, the therapeutic protocol of H. pylori-related diseases such as chronic atrophic gastritis, spasmolytic peptide-expressing metaplasia, intestinal metaplasia and even intraepithelial neoplasia are still limited. The limitations of conventional therapy divert people's attention to complementary and alternative medicine, and some traditional medicine (herbal and animal medicine in China, Japan, Brazil, and Africa, for example) have been proven to have therapeutic effects on H. pylori-induced gastric diseases. More scientific research focused on the effect and mechanism of traditional medicine is absolutely necessary and significant.
This research topic aims at elucidating the pathogenesis of Helicobacter pylori-induced diseases and providing insights into therapy, including novel therapeutic approaches and traditional medicines. Submissions on the following specific topics are welcome:
• The mechanism underlying the pathogenesis of H. pylori-induced chronic atrophic gastritis, spasmolytic peptide-expressing metaplasia, intestinal metaplasia, intraepithelial neoplasia and gastric cancer.
• Basic or clinical studies focused on traditional medicine for the treatment of H. pylori-related gastric diseases (including chemical agent-induced models similar to H. pylori infection).
• Basic or clinical studies on novel therapeutics for the treatment of H. pylori-related disease (including alternatives or adjuncts to antibiotic therapy)
• The specific survival and infection strategies of H. pylori and the mechanism of its stable colonization in the stomach
• The role of anti-acid, motile, adhesive, biofilm formation, and intracellular survival ability in the pathogenesis of H. pylori-induced diseases.